Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of Mutations and Outcome in Gastrointestinal Stromal Tumors with Deep Learning: A Multicenter, Multinational Study.

medRxiv : the preprint server for health sciences·2026
Same author

Treatment outcome of NSCLC patients with BRAF<sup>non-V600E</sup> mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.

ESMO open·2025
Same author

Superficial fibromas with CTNNB1 mutation.

Genes, chromosomes & cancer·2024
Same author

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer-final results of the EUCROSS trial.

ESMO open·2024
Same author

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.

Blood·2022
Same author

Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Related Experiment Video

Updated: Jul 9, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

[Molecular targets for diagnostics and therapy--new challenges for pathologists].

S Merkelbach-Bruse1, E Wardelmann, L Heukamp

  • 1Institut für Pathologie, Universität Bonn.

Verhandlungen Der Deutschen Gesellschaft Fur Pathologie
|November 27, 2007
PubMed
Summary

Molecular diagnostics links genetic changes to tumor phenotypes, aiding diagnosis and targeted therapies. Gastrointestinal stromal tumors (GISTs) exemplify using mutations for predicting treatment response and resistance.

Related Experiment Videos

Last Updated: Jul 9, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

Area of Science:

  • Molecular genetics and cell biology
  • Signal transduction pathways
  • Cancer biology

Context:

  • Advances in molecular genetics have identified key signal transduction pathways.
  • Understanding genetic aberrations driving malignant transformation and tumor progression is crucial.
  • Specific tumor phenotypes are increasingly linked to distinct genetic alterations.

Purpose:

  • To highlight the role of molecular diagnostics in tumor classification.
  • To emphasize the identification of therapeutic targets through mutation analysis.
  • To discuss the application of molecular insights in treating Gastrointestinal Stromal Tumors (GISTs).

Summary:

  • Molecular diagnostics aids in discriminating specific tumor entities by linking phenotypes to genetic changes.
  • Identifying critical mutations predicts tumor biology and response to targeted therapies, such as receptor inhibitors for GISTs.
  • Secondary mutations can cause therapeutic resistance, necessitating combinatorial approaches and advanced molecular pathology techniques.

Impact:

  • Molecular diagnostics is vital for accurate tumor diagnosis and classification.
  • Targeted therapies based on specific mutations offer personalized treatment strategies.
  • Predictive pathology and monitoring treatment response are evolving challenges in molecular pathology.